🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT06928870
Starting soon Not applicable

The Effect of Controlled Hypotension

NCT06928870 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-04-30
Last updated
2025-04-15

Condition(s) studied

Cerebral HypoperfusionHypotension

Investigational drug(s) / intervention(s)

MAP 55-65 mmHgMAP 66-75 mmHg

MAP 55-65 mmHg: MAP will be maintained between 55-65 mmHg during anesthesia.

MAP 66-75 mmHg: MAP will be maintained between 66-75 mmHg during anesthesia.

Study summary

Controlled hypotension is currently used in spinal surgery to reduce bleeding at the surgical site, improve the surgeon's visibility, and decrease intraoperative blood loss. Although controlled hypotension is considered a beneficial method from a surgical perspective, it is important to be cautious about its side effects. One such side effect is cerebral perfusion insufficiency, which can be managed by monitoring cerebral circulation through regional cerebral oxygen saturation (rSO2).

The aim of this study is to compare the effects of controlled hypotension at specific MAP ranges on cerebral oxygen saturation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Aged 18-65 years * ASA I-III risk group * BMI between 18-40 * Baseline blood pressure below 140/90 mmHg * Scheduled to undergo spinal surgery (2-4 level instrumentation) Exclusion Criteria: * Below 18 or above 65 years old * Advanced comorbidities * ASA IV or higher * Baseline blood pressure above 140/90 mmHg * History of bleeding diathesis * Use of anticoagulant medications * BMI below 18 or above 40 * History of previous spinal surgery

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ankara Etlik City Hospital Ankara Varlık Mahallesi Yenimahalle

More Ankara Etlik City Hospital trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06928870 on ClinicalTrials.gov ↗ ← All trials in Turkey